JP2024023232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023232A5 JP2024023232A5 JP2023189072A JP2023189072A JP2024023232A5 JP 2024023232 A5 JP2024023232 A5 JP 2024023232A5 JP 2023189072 A JP2023189072 A JP 2023189072A JP 2023189072 A JP2023189072 A JP 2023189072A JP 2024023232 A5 JP2024023232 A5 JP 2024023232A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- identity
- nucleic acid
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025184908A JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680297P | 2018-06-04 | 2018-06-04 | |
| US62/680,297 | 2018-06-04 | ||
| JP2020567215A JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| PCT/US2019/035384 WO2019236577A2 (en) | 2018-06-04 | 2019-06-04 | Muc16 specific chimeric antigen receptors and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Division JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184908A Division JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023232A JP2024023232A (ja) | 2024-02-21 |
| JP2024023232A5 true JP2024023232A5 (https=) | 2024-10-16 |
| JP7827673B2 JP7827673B2 (ja) | 2026-03-10 |
Family
ID=68764543
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Pending JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2023189072A Active JP7827673B2 (ja) | 2018-06-04 | 2023-11-06 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2025184908A Pending JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Pending JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184908A Pending JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11319380B2 (https=) |
| EP (1) | EP3802615A4 (https=) |
| JP (3) | JP2021525534A (https=) |
| KR (1) | KR20210021493A (https=) |
| CN (2) | CN121852427A (https=) |
| AU (1) | AU2019282620B2 (https=) |
| CA (1) | CA3101641A1 (https=) |
| IL (1) | IL278976A (https=) |
| SG (1) | SG11202011895VA (https=) |
| WO (1) | WO2019236577A2 (https=) |
| ZA (3) | ZA202008065B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3697438A4 (en) * | 2017-10-18 | 2021-08-18 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS WITH SPACERS |
| SG11202104524YA (en) * | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021256522A1 (ja) * | 2020-06-17 | 2021-12-23 | 国立大学法人京都大学 | キメラ抗原受容体発現免疫担当細胞 |
| WO2022140388A1 (en) * | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| JP2024504585A (ja) * | 2021-01-19 | 2024-02-01 | オブシディアン セラピューティクス， インコーポレイテッド | Ｔ細胞及び腫瘍浸潤リンパ球の拡張のための組成物及び方法 |
| KR20230147619A (ko) * | 2021-02-26 | 2023-10-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 외인적으로 도입된 사이토카인을 발현하는 조작된 면역이펙터 세포 |
| US20250145950A1 (en) * | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN115819613B (zh) * | 2022-05-10 | 2023-10-20 | 四川大学华西医院 | 基于msln前体蛋白构建的嵌合抗原受体免疫细胞制备及其应用 |
| CN116196402A (zh) * | 2022-11-01 | 2023-06-02 | 山东大学齐鲁医院 | 表达双特异性抗体的溶瘤腺病毒联合cart在肿瘤治疗中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| NZ563370A (en) | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| KR101597842B1 (ko) | 2008-01-11 | 2016-02-25 | 가부시키가이샤 진 테크노 사이언스 | 인간화된 항-알파9 인테그린 항체 및 그의 용도 |
| DK2496698T3 (en) * | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| PT2552959T (pt) * | 2010-03-26 | 2017-04-21 | Memorial Sloan Kettering Cancer Center | Anticorpos para muc16 e métodos de utilização dos mesmos |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3126390B2 (en) * | 2014-04-03 | 2026-01-07 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| AU2016243124A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | CAR T-cell therapy directed to LHR for the treatment of solid tumors |
| CN108064246A (zh) | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| WO2017040945A1 (en) | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| SG11201810640RA (en) | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| WO2018009811A1 (en) * | 2016-07-08 | 2018-01-11 | Genentech, Inc. | Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment |
| MA45779A (fr) | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Polypeptides immunomdulateurs et compositions et procédés associés |
| EP3522933B1 (en) * | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| CN107557336B (zh) * | 2017-09-15 | 2020-02-14 | 山东兴瑞生物科技有限公司 | 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用 |
-
2019
- 2019-06-04 US US16/431,193 patent/US11319380B2/en active Active
- 2019-06-04 WO PCT/US2019/035384 patent/WO2019236577A2/en not_active Ceased
- 2019-06-04 AU AU2019282620A patent/AU2019282620B2/en active Active
- 2019-06-04 CA CA3101641A patent/CA3101641A1/en active Pending
- 2019-06-04 JP JP2020567215A patent/JP2021525534A/ja active Pending
- 2019-06-04 CN CN202610008767.1A patent/CN121852427A/zh active Pending
- 2019-06-04 CN CN201980052129.8A patent/CN112533957B/zh active Active
- 2019-06-04 KR KR1020207038033A patent/KR20210021493A/ko active Pending
- 2019-06-04 SG SG11202011895VA patent/SG11202011895VA/en unknown
- 2019-06-04 EP EP19815389.2A patent/EP3802615A4/en active Pending
-
2020
- 2020-11-25 IL IL278976A patent/IL278976A/en unknown
- 2020-12-23 ZA ZA2020/08065A patent/ZA202008065B/en unknown
-
2021
- 2021-12-22 ZA ZA2021/10780A patent/ZA202110780B/en unknown
-
2022
- 2022-02-04 US US17/650,018 patent/US11981746B2/en active Active
- 2022-02-04 US US17/650,025 patent/US11976134B2/en active Active
-
2023
- 2023-11-06 JP JP2023189072A patent/JP7827673B2/ja active Active
- 2023-12-19 ZA ZA2023/11718A patent/ZA202311718B/en unknown
-
2024
- 2024-04-05 US US18/628,575 patent/US20240368305A1/en active Pending
-
2025
- 2025-10-31 JP JP2025184908A patent/JP2026031977A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023232A5 (https=) | ||
| US12371489B2 (en) | Car based immunotherapy | |
| US9868961B2 (en) | Methods and compositions for localized secretion of anti-CTLA-4 antibodies | |
| JP2024138280A5 (https=) | ||
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| EP3599251A1 (en) | Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof | |
| JP7636650B2 (ja) | 二量体形成剤調節性免疫受容体複合体 | |
| JP7833569B2 (ja) | Ｂｃｍａ－ｃｄ１９を標的とする二重特異性キメラ抗原受容体およびその用途 | |
| JP2021525534A5 (https=) | ||
| KR20180057723A (ko) | 항-cd30 키메라성 항원 수용체 | |
| CN107936120B (zh) | Cd19靶向性的嵌合抗原受体及其制法和应用 | |
| JP7431735B2 (ja) | Ｄａｒｉｃインターロイキン受容体 | |
| AU2018385694B2 (en) | NKG2D DARIC receptors | |
| JPWO2019236577A5 (https=) | ||
| JP2026506591A (ja) | 天然タンパク質ｔｓｈを抗原結合部位とした、ｔｓｈｒを標的とするｃａｒ－ｔ細胞の構築 | |
| WO2023093888A1 (zh) | 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用 | |
| CN109593137B (zh) | 抗cd20抗体的新型cd20-car载体的构建及应用 | |
| HK40123857A (en) | Bispecific chimeric antigen receptor targeting bcma-cd19 and application thereof | |
| WO2024179518A1 (zh) | 具有优化的itam结构域及cd28与4-1bb双共刺激分子的双靶点car-t | |
| WO2024190856A1 (ja) | 抗ｂｃｍａ抗体およびキメラ抗原受容体 | |
| KR20240111378A (ko) | Nkg2d 키메라 수용체, 이를 발현하는 형질전환 세포 및 이의 항암 용도 | |
| HK40100191A (zh) | 用於同种异体细胞治疗的通用嵌合抗原受体表达免疫细胞 |